News und Analysen
Biogen Inc. Buys Its Way Out of Competition
Biogen (NASDAQ: BIIB) is following the old saying, "If you can't beat 'em, join 'em" for its multibillion drug Tecfidera or, more accurately, "If you might not be able to beat 'em later, license....
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
These big pharma stocks have something for everyone. Income investors love the dividends Eli Lilly and Co. (NYSE: LLY) and Merck & Co., Inc. (NYSE: MRK) pay each quarter, while dreams of....
What Will the Average American Pay for Obamacare in 2018?
Big changes are in store for consumers who are planning to purchase an Obamacare (officially the Affordable Care Act, or ACA) plan in 2018. Though the enrollment period is ongoing and remains the....
3 Top Diabetes Stocks to Buy Now
Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs....
5 Cancer Types With the Poorest Long-Term Outlook
There's arguably no scarier diagnosis a patient can receive from their doctor than cancer. But the grim reality, based on data from the National Cancer Institute's Surveillance, Epidemiology, and....
How to Diversify Your Healthcare Investments
On this week's episode of Industry Focus: Healthcare, analysts Kristine Harjes and Todd Campbell get back to basics and explain what you need to know about diversifying your portfolio, especially....
Agilent Technologies (A) Q4 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Agilent Technologies (NYSE: A) Q4 2017 Earnings Conference CallNov. 20, 2017 4:30 p.m. ETOperatorContinue readingSource: Fool.com
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
At a recent healthcare conference, Gilead Sciences (NASDAQ: GILD) CEO John Milligan laid out his top three priorities for 2018. Here's what he said (this and all other quotes courtesy of S&P....
Better Buy: AbbVie Inc. vs. Johnson & Johnson
They're partners. And they're rivals. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. However, the two big drugmakers compete against each....
Will UnitedHealth Group Do a Stock Split in 2018?
Healthcare remains in flux, with changing policies concerning the Affordable Care Act and health insurance more broadly having a huge impact on the industry. As a leader in the health insurance....
3 Stocks That Have Doubled and Still Have Room to Grow
The S&P 500 is hovering near an all-time high and has had a great year in 2017, so it's not a surprise that many stocks have delivered exceptional performance recently. However, just because a....
Is Merck & Co. Inc. a Buy?
If 2017 ended right now, it would be the worst year for Merck & Co. (NYSE: MRK) stock since the financial crisis of 2008. There are still several weeks remaining before the year ends, of....
Ending Obamacare's Individual Mandate Would All but Kill an Already Compromised Law
The winds of change are in the air in Washington, and it has absolutely nothing to do with turkey dinners and pumpkin-spiced lattes. The long-awaited tax reform from Republicans, the current....
3 Top Medical Device Stocks to Buy Now
Healthcare investors tend to focus all of their attention on biotechnology or pharmaceutical stocks. That's a shame, because the medical device industry has some wonderful traits that make it a....
Better Buy: Biogen Inc. vs. Gilead Sciences
Historically, Biogen (NASDAQ: BIIB) has definitely been a better stock than Gilead Sciences (NASDAQ: GILD). Whether you look at the last three, five, 10, 25 years, or even so far in 2017, Biogen....
Here's Why Nektar Therapeutics Is Skyrocketing 70% in November
After the company told investors that it plans to file for Food and Drug Administration approval for a drug that could disrupt the $12 billion market for opioid painkillers, Nektar Therapeutics....
Is Intuitive Surgical, Inc. a Buy?
What goes up must come down, right?That's probably been the hope for investors wanting to buy Intuitive Surgical (NASDAQ: ISRG) stock on a dip. So far this year, though, there hasn't been much of....
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
What's the best big pharma stock?Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others.....
Unternehmensanalyse Gilead Sciences
Gilead Sciences ist ein sehr profitables Unternehmen aus der Pharma- und Biotechnik Branche. Das Unternehmen produziert dabei Medikamente und Präparate für diverse Krankheiten. Die wichtigsten....
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
Donald Trump's next top pick for running the Department of Health and Human Services (HHS) is Eli Lilly & Co. (NYSE: LLY) executive Alex Azar, and that's drawing the ire of patient advocates....
3 Top Big Pharma Dividend Stocks You Can Buy Right Now
Big pharma stocks have long been favorites for dividend-seeking investors, and for good reason. Major pharmaceutical companies typically generate strong cash flow, which allows them to pay high....
What Investors Need to Know About Investing in Low PE Stocks
What do Warren Buffett, Ben Graham, Seth Klarman, and Peter Lynch all have in common? Besides being wildly successful investors, they're all are adherents to value investing, a method where one....
So, This Is What the End of Obamacare Looks Like
For better or worse, the Affordable Care Act (ACA) has been the law of the land since it was signed into law in March 2010 and officially was enacted in the individual insurance markets in 2014.In....
3 Growth Stocks for Farsighted Investors
Investing in so-called growth stocks can be as exciting as it is frustrating. All too often, investors who own growth stocks panic when they realize that the road to market-beating gains is....
Obamacare Was Destined to Fail, Even Without Trump
In case you missed it, open enrollment for the Affordable Care Act's (ACA) fifth year is underway, through Dec. 15, 2017, or perhaps a bit longer in select states. The upcoming year of enrollment....